FDA-Approved Medications for Alzheimer's Disease: A Practical Guide for Caregivers and Early-Stage Patients

This article explains the FDA-approved medications for Alzheimer's disease, including both older symptom-treating drugs and newer disease-modifying therapies. These medications are not cures, but they can help manage symptoms or slow progression for some people. Understanding what each drug does, who it is for, and what to expect can help you have informed conversations with your healthcare team and make decisions that fit your or your loved one's unique situation. You are not alone in navigating this—there are concrete steps and tools to help you along the way.

Key points

FDA-approved Alzheimer's medications fall into two groups: older symptom-treating drugs (cholinesterase inhibitors, memantine) and newer disease-modifying drugs (lecanemab, donanemab) for early-stage disease.
These drugs are not cures—they can slow progression or improve symptoms temporarily, but the disease continues.
Newer anti-amyloid drugs require a confirmed amyloid positive test and regular infusions; they carry risks of brain swelling/bleeds that require MRI monitoring.
For sleep, only suvorexant (Belsomra) is FDA-approved for Alzheimer's; other sleep aids carry black box warnings and should be avoided.
Non-drug approaches (routine, environment, communication) should be tried first for behavioral symptoms before medications.
Always work closely with a specialist (neurologist, geriatrician) and keep a detailed medication log to track effects and side effects.

What Are the FDA-Approved Alzheimer's Medications?

The U.S. Food and Drug Administration (FDA) has approved several medications for Alzheimer's disease, and they fall into two main categories: older drugs that treat symptoms and newer drugs that target the underlying disease process. The older, well-established medications include donepezil (Aricept), rivastigmine (Exelon), galantamine (Razadyne), and memantine (Namenda). Donepezil, rivastigmine, and galantamine are called cholinesterase inhibitors—they work by boosting levels of a brain chemical involved in memory and thinking. Memantine works on a different chemical system (glutamate) and is often used for moderate to severe stages. These drugs do not stop the disease, but they can temporarily improve or stabilize cognitive symptoms for some people, typically for months to a few years. As one geriatrician explains, these medications are not a cure, but they can modestly slow decline and help maintain function for a period of time.

Newer Disease-Modifying Therapies: Lecanemab and Donanemab

In the last few years, two new drugs—lecanemab (Leqembi) and donanemab (Kisunla)—have been approved for early-stage Alzheimer's disease. These are anti-amyloid antibodies that target and remove amyloid plaques in the brain, a hallmark of Alzheimer's. Clinical trials showed that lecanemab slowed cognitive decline by about 27% over 18 months compared to placebo, and donanemab showed similar modest slowing. These drugs are not a cure—people on them still decline, but at a slower rate. They are only approved for people with mild cognitive impairment or mild dementia due to Alzheimer's, confirmed by amyloid PET scan or spinal fluid test. They require regular intravenous infusions (every two weeks for lecanemab, every four weeks for donanemab) and monitoring for side effects, including brain swelling or small bleeds (ARIA). Real-world data from clinics and memory centers in 2025 shows that these drugs can be used safely and effectively outside of clinical trials, with patient satisfaction reported.

Medications for Sleep and Behavioral Symptoms

The FDA has also approved suvorexant (Belsomra) for insomnia in people with mild-to-moderate Alzheimer's. This drug works by blocking a chemical messenger involved in wakefulness, helping with sleep onset and maintenance. It is important to note that many other sleep aids—like benzodiazepines, 'Z-drugs' (zolpidem, zaleplon), and antipsychotics—are not FDA-approved for dementia-related sleep problems and carry black box warnings about increased risk of stroke and death in older adults with dementia. For agitation, two newer medications have been approved: brexpiprazole (Rexulti) and, more recently, a second drug (as of 2024). Always discuss any behavioral medication with your clinician, as non-drug approaches should be tried first.

General caregiving information, not medical advice. Check medications and major care changes with your clinician.

Step-by-step

Schedule an evaluation with a neurologist or geriatrician specializing in memory disorders; bring a current medication list and a detailed symptom timeline to confirm diagnosis and stage.
If diagnosed with early-stage Alzheimer's (mild cognitive impairment or mild dementia), ask whether lecanemab (Leqembi) or donanemab (Kisunla) is appropriate; these require a positive amyloid PET scan or spinal fluid test, and discuss APOE4 genetic testing beforehand since carriers—especially homozygotes—face a higher risk of ARIA (brain swelling/bleeding).
For mild-to-moderate Alzheimer's, discuss starting a cholinesterase inhibitor (donepezil, rivastigmine patch, or galantamine); begin low and titrate gradually to minimize nausea, diarrhea, appetite loss, dizziness, or bradycardia.
During the first weeks of any new medication, watch for side effects—gastrointestinal symptoms and dizziness with cholinesterase inhibitors; headache, confusion, vision changes, dizziness, or seizures with anti-amyloid drugs (signs of ARIA)—and report new symptoms to the prescriber promptly.
Reassess after 3–6 months on a stable dose; if no benefit or side effects outweigh gains, stop or switch. Use a written log of memory, behavior, and function changes to guide this conversation.
For moderate-to-severe Alzheimer's, add memantine (Namenda) alone or with a cholinesterase inhibitor (available as Namzaric); it may help thinking and daily function.
For significant sleep problems, try consistent bedtime routines, limited caffeine, and a calm dark room first; if insufficient, ask about suvorexant (Belsomra)—the only FDA-approved sleep drug for mild-to-moderate Alzheimer's—and watch for impaired alertness, mood changes, or complex sleep behaviors.
For agitation or psychosis, try non-drug approaches (identify triggers, redirect, ensure comfort) first; if needed, ask about brexpiprazole (Rexulti). Older antipsychotics (risperidone, olanzapine) are not FDA-approved for dementia-related psychosis and carry a black box warning—reserve for severe cases at lowest effective dose.
Attend all follow-ups and required imaging: anti-amyloid therapies need periodic MRIs to detect silent ARIA; other medications may need occasional blood tests. Stay in touch with the care team between visits.

What not to do

Do not expect these medications to cure or reverse Alzheimer's; they may modestly slow progression or ease symptoms. Unrealistic expectations can lead to abandoning a treatment that is helping.
Do not stop or adjust doses on your own, especially cholinesterase inhibitors; abrupt discontinuation can cause rapid, sometimes irreversible cognitive decline. Any changes should be tapered under medical supervision.
Do not use over-the-counter sleep aids (e.g., diphenhydramine/Benadryl) or unregulated memory supplements without checking with a doctor or pharmacist; many have anticholinergic effects that worsen confusion and increase fall risk.
Do not dismiss new headaches, confusion, vision changes, or dizziness in someone on lecanemab or donanemab as 'just a bad day'—these can signal ARIA, requiring prompt evaluation and sometimes emergency treatment.
Do not rely on medication alone; combine it with cognitive stimulation, physical activity, social engagement, a balanced diet, and a predictable daily routine.

Practical tools

Medication Tracking Log
A notebook or free app (e.g., Medisafe) with columns for date, medication and dose, time taken, side effects, and brief notes on cognition, mood, or function; bring to each appointment so the prescriber can identify patterns and adjust confidently.
Pill Organizer with Daily Reminders
A weekly AM/PM organizer paired with a phone alarm or smart-speaker routine. For rivastigmine patches, write the application date on the patch with a marker and rotate sites to prevent skin irritation.
Doctor Visit Preparation Checklist
Before each appointment, write down current symptoms, any side effects, and 2–3 specific medication questions (e.g., 'Is this still the right dose?' or 'Are there newer options?'); bring the full medication list and a trusted family member to help take notes.
Non-Drug Sleep Routine Checklist
A posted daily checklist covering a fixed bedtime and wake time, no caffeine after early afternoon, no screens an hour before bed, a dim and cool bedroom, and a brief wind-down ritual (warm tea, soft music, gentle stretching); use for at least two to three weeks before asking about sleep medication.
ARIA Symptom Alert Card
A wallet-sized card for anyone on lecanemab or donanemab listing the drug name, prescriber contact, and urgent warning signs (sudden headache, confusion, vision changes, dizziness, nausea, or seizures) with instructions to seek same-day medical care; share copies with family, caregivers, and the primary care doctor.

Which allergy medications are safe for seniors and which should be avoided?

For seniors with Alzheimer's, avoid diphenhydramine (Benadryl) and other first-generation antihistamines as they can worsen confusion and fall risk; safer choices include loratadine (Claritin) or cetirizine (Zyrtec), but always check with the doctor first before adding any new medication.

Does continuing donepezil delay nursing home placement in moderate-to-severe Alzheimer's?

Yes, studies show continuing donepezil in moderate-to-severe Alzheimer's can delay nursing home placement by several months, so talk with the specialist before stopping it even if symptoms seem to be progressing.

What is the PrecivityAD blood test and should I use it?

The PrecivityAD blood test measures amyloid proteins to help detect Alzheimer's-related brain changes, but it's not a standalone diagnosis—ask the neurologist if it would be useful for clarifying your loved one's condition before pursuing newer treatments.

Does starting memantine delay nursing home placement in moderate-to-severe Alzheimer's?

Yes, adding memantine to donepezil in moderate-to-severe Alzheimer's has been shown to delay nursing home placement and reduce caregiver burden, so discuss this combination with the doctor if it hasn't been tried yet.

How does Alzheimer's affect the likelihood of stopping statins, and should they be continued?

Alzheimer's can make it harder to take daily statins reliably, but continuing them is often recommended because managing vascular health helps slow overall decline—use a pill organizer and a daily routine to keep it consistent.

How do neuroleptic medications affect swallowing and pneumonia risk in severe Alzheimer's?

Neuroleptic medications like antipsychotics can impair swallowing and increase pneumonia risk in severe Alzheimer's, so they should only be used for severe agitation or psychosis after non-drug approaches fail, and at the lowest effective dose with close monitoring.

What is benfotiamine and how might it help Alzheimer's?

Benfotiamine is a form of vitamin B1 being studied for possible benefits in Alzheimer's, but it is not FDA-approved for the disease—discuss with the doctor if it's worth trying as a supplement, but don't rely on it as a primary treatment.

When is memantine recommended for moderate to severe Alzheimer's disease?

Memantine is recommended for moderate to severe Alzheimer's, typically started when donepezil alone is no longer enough, to help manage symptoms and slow functional decline—ask the neurologist if it's the right time to start.

What does rivastigmine do for Alzheimer's symptoms?

Rivastigmine is a cholinesterase inhibitor that can temporarily improve thinking, memory, and daily function in mild to moderate Alzheimer's by boosting acetylcholine levels, and it's available as a patch that may be easier to tolerate than pills.

Should we try escitalopram or citalopram for agitation instead of antipsychotics?

Yes, escitalopram or citalopram are often safer first-line options for agitation than antipsychotics, as they have lower risks of side effects like stroke and sedation—ask the doctor about starting a low dose and monitoring for improvement over several weeks.

When should medication be used for paranoid delusions in Alzheimer's, and what are the risks?

Medication for paranoid delusions should only be considered when the beliefs cause significant distress or danger to the person or others, and after trying non-drug calming strategies; antipsychotics carry serious risks like falls and pneumonia, so they need careful specialist oversight.

Can melatonin help with sleep or cognitive decline in Alzheimer's?

Melatonin may help a little with sleep onset in Alzheimer's, but it does not slow cognitive decline and can cause daytime grogginess—try a low dose (1-3 mg) at bedtime only after establishing a consistent bedtime routine first.

How can I submit a public comment to influence Medicare's coverage decision for Alzheimer's drugs?

To submit a public comment on Medicare coverage for Alzheimer's drugs, go to the CMS website during open comment periods, write a brief personal story about the drug's impact on your loved one, and follow the instructions on the official Federal Register notice.

Does Medicare cover new anti-amyloid Alzheimer's drugs?

Medicare covers new anti-amyloid drugs like lecanemab and donanemab only for people with mild cognitive impairment or early-stage Alzheimer's who have confirmed amyloid buildup, and the treatment requires regular infusions and MRI monitoring—check with the specialist to see if your loved one qualifies.

Should I consider cognitive enhancers for a person with Alzheimer dementia?

Yes, cognitive enhancers like donepezil, rivastigmine, or memantine are worth considering as they can help stabilize symptoms or slow decline for many people; the neurologist can help pick the best one based on your loved one's stage and tolerance.

Do these drugs cure Alzheimer's, and what should I be cautious about?

No, these drugs do not cure Alzheimer's—they only slow progression or improve symptoms temporarily; be cautious of unproven supplements or treatments, and always track any new medication's effects and side effects in a log to share with the doctor.

What medications are recommended to slow cognitive decline in Alzheimer's dementia (including hypertension, diabetes, and vascular risk management)?

To slow cognitive decline, manage hypertension, diabetes, and vascular risks with standard medications (like statins or blood pressure drugs) as prescribed, since a healthy heart supports brain health—use a medication log and weekly check-ins with the primary care doctor to stay on track.

Discuss with your clinician

Ask your doctor: 'Is my loved one a candidate for lecanemab or donanemab? What tests are needed to confirm eligibility?'

Discuss: 'What are the specific risks of brain swelling or bleeding (ARIA) with these new drugs, and how will we monitor for them?'

Ask: 'If we start a cholinesterase inhibitor, what is the plan for dose titration and how long should we try it before assessing benefit?'

Inquire: 'Are there any drug interactions between Alzheimer's medications and my loved one's other prescriptions (e.g., blood thinners, antidepressants)?'

Discuss: 'For sleep problems, is suvorexant (Belsomra) appropriate? What are the side effects and how should we monitor for them?'

Ask: 'If agitation occurs, what non-drug strategies should we try first? When would you consider a medication like brexpiprazole?'